Article
Oncology
Naama Margolis, Hanna Moalem, Tomer Meirson, Gilli Galore-Haskel, Ettai Markovits, Erez N. Baruch, Bella Vizel, Avner Yeffet, Julia Kanterman-Rifman, Assaf Debby, Michal J. Besser, Jacob Schachter, Gal Markel
Summary: The interaction between melanoma cells and T cells can enhance the chemotaxis of new T cells. ADAR1-p150 expression is correlated with immune infiltration and can be induced by immunotherapy. ADAR1 regulates T cell migration through the secretion of chemokines.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Svenja Meierjohann
Summary: Melanomas and melanocytes are frequently exposed to UV, resulting in DNA damage and reactive oxygen stress related harm. This can lead to multinucleation or polyploidy, with the cells either experiencing mitotic catastrophe and death or surviving and acquiring new features to adapt to stress. This review focuses on polyploidy inducers in melanoma, their effects on transcriptional reprogramming and phenotypic adaptation, and the significance of polyploid melanoma cells in therapy resistance.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Brigitte Dreno, Amir Khammari, Agnes Fortun, Virginie Vignard, Soraya Saiagh, Tiffany Beauvais, Nicolas Jouand, Sylvain Bercegay, Sylvain Simon, Francois Lang, Nathalie Labarriere
Summary: The study demonstrated the feasibility and safety of using Melan-A and MELOE-1 specific T cells for ACT in metastatic melanoma patients, but the clinical efficacy can be further enhanced by selecting highly reactive T cells based on PD-1 and TIGIT co-expression and combining with ICI such as anti-PD-1.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Jasmina Bier, Sebastian M. Steiger, Holger M. Reichardt, Fred Luehder
Summary: The study investigated the impact of antigen priming on the sensitivity of T cells to glucocorticoid-induced apoptosis, revealing the different responses of antigen-primed effector T cells compared to naïve T cells to synthetic GCs in vitro and in vivo. The findings suggest that antigen priming influences the sensitivity of T cells to therapeutic GCs in the context of inflammatory diseases.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Florian Maerkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L. Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Mueller, Lina Majed, Matthias Seifert, Anna-Kristina Kluever, Theo Lorenzini, Ruth Gruenmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P. Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Summary: Melanoma is an immune sensitive disease, and immune check point blockade has shown activity. However, TIL therapy after ICB failure has shown promising efficacy, indicating the potential of cellular therapies. To overcome limitations of TIL treatment, a controlled adoptive cell therapy approach using synthetic agonistic receptors and bispecific antibodies targeting melanoma-associated antigens is proposed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Rodrigo C. C. De Marco, Hector J. J. Monzo, Paivi M. Ojala
Summary: With the continuous advancements in immunotherapy and precision medicine, adoptive cell therapy (ACT) has emerged as a new treatment approach in oncology. Chimeric antigen receptor (CAR) T cells, genetically modified lymphocytes, have shown promising results in targeting and killing cancer cells. Commercialization of CAR T cell therapy has paved the way for future bright developments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Yutong Liu, Kwasi Adu-Berchie, Joshua M. Brockman, Matthew Pezone, David K. Y. Zhang, Jingyi Zhou, Jason W. Pyrdol, Hua Wang, Kai W. Wucherpfennig, David J. Mooney
Summary: This study uses nanotechnology to improve adoptive T cell transfer (ACT) therapies by metabolically labeling T cells with unnatural sugar nanoparticles, allowing direct conjugation of antitumor cytokines onto the T cell surface. This approach effectively enhances the efficacy of ACT therapies.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Ramon Yarza, Mateo Bover, Mercedes Herrera-Juarez, Macarena Rey-Cardenas, Luis Paz-Ares, Jose A. Lopez-Martin, John Haanen
Summary: This study conducted a systematic review and meta-analysis to assess the primary efficacy of TCR-based adoptive cell therapy in cutaneous melanoma. The results showed promising antitumor activity and survival for TCR-T therapy, with a significantly higher benefit for cancer/testis antigen targeting cells.
Article
Biochemistry & Molecular Biology
Su Yin Lim, Sara Alavi, Zizhen Ming, Elena Shklovskaya, Carina Fung, Ashleigh Stewart, Helen Rizos
Summary: Our study found that tumor necrosis factor alpha (TNF alpha) can influence the differentiation status and immune inhibition of melanoma cells, with different impacts on different melanoma cells. TNF alpha showed poor induction of antigen presentation molecules but readily induced the PD-L2 immune checkpoint in melanoma cells. Our results suggest that TNF alpha promotes dynamic changes in melanoma cells that may favor immunotherapy resistance.
Article
Oncology
Ramon Yarza, Mateo Bover, Mercedes Herrera-Juarez, Macarena Rey-Cardenas, Luis Paz-Ares, Jose A. Lopez-Martin, John Haanen
Summary: TCR-based ACT has shown promising results in treating metastatic cutaneous melanoma, with a notable antitumor activity and survival benefit.
Review
Biochemistry & Molecular Biology
Ali R. Jazirehi
Summary: Metastatic melanoma is the deadliest form of skin cancer, with traditional treatments being ineffective in inducing tumor regression at a high rate. New treatments like immune checkpoint inhibitors, targeted therapy, and TCR-engineered T cells aim to boost the immune system's ability to recognize and eradicate tumors, but resistance limits their effectiveness.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Dermatology
Takashi Inozume
Summary: Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) for melanoma is a successful cancer immune therapy, with around 20% of patients achieving a durable complete response. Efforts have been made to enhance the effect and simplify the protocol of TIL therapy, resulting in a simple and effective current TIL therapy that has been propagated to other institutes and countries. Translational research using clinical samples derived from durable responders helps to elucidate important elements for developing more effective cancer immune therapies.
EXPERIMENTAL DERMATOLOGY
(2023)
Review
Immunology
Aida Karachi, Farhad Dastmalchi, Saina Nazarian, Jianping Huang, Elias J. Sayour, Linchun Jin, Changlin Yang, Duane A. Mitchell, Maryam Rahman
Summary: Evading T cell surveillance is a key aspect of cancer development. Patients with solid tissue malignancies like glioblastoma often experience immune dysfunction, particularly in T cell function. Standard treatments can worsen T cell dysfunction, but strategies like adoptive T cell transfer, including CAR T cells, offer potential for reinvigorating immune responses against cancer. However, there are risks of depletion and dysfunction in these adoptively transferred T cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Enrique J. Arenas, Alex Martinez-Sabadell, Irene Rius Ruiz, Macarena Roman Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquin Arribas
Summary: Immunotherapy has shown promise in cancer treatment, with T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) being potential tools for this approach. This study reveals that disruption of interferon-gamma signaling, including downregulation of JAK2, in cancer cells confers resistance to T cell-mediated cytotoxicity directed against HER2, highlighting a potential mechanism for resistance to T cell-engaging therapies.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Qian Sun, Daniel Novak, Laura Hueser, Juliane Poelchen, Huizi Wu, Karol Granados, Aniello Federico, Ke Liu, Tamara Steinfass, Marlene Vierthaler, Viktor Umansky, Jochen Utikal
Summary: FOXD1 plays a role in regulating melanoma cell migration and invasion, with its upregulation associated with increased resistance of melanoma cells to drug treatment; through the regulation of FOXD1, CTGF can affect the sensitivity of melanoma cells to drug treatment.
INTERNATIONAL JOURNAL OF CANCER
(2021)